CRI Worldwide, which recently acquired Lifetree Clinical Research, has united the two companies under the new brand of CRI Lifetree. The combined company includes CRI’s expertise in psychiatry and in complex studies with Lifetree’s clinical trial management and site expertise in Phase I-III pain management and abuse liability studies.

“CRI Lifetree is grounded in sound science,” said Alice Jackson, CRI Lifetree’s president. “We give our clients the innovation they are looking for, from entrepreneurial first-in-human study design, to solutions for specialized human abuse liability research.”

“We’re off to a great start; the company is busier than ever,” commented Jeff Kinell, CRI Lifetree’s chief executive officer. “Since the acquisition, our clients have continued to receive the highest quality service and results, while enriching the early stage clinical research landscape for our sponsors.”

CRI Lifetree provides specialized, multi-therapeutic inpatient and outpatient early stage research as well as Phase I-IV services and access to specific patient populations for complex clinical research programs.